{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T20:51:39Z","timestamp":1763499099154,"version":"build-2065373602"},"reference-count":22,"publisher":"CSIRO Publishing","issue":"2","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":4634,"URL":"https:\/\/doi.org\/10.1071\/journalslicense"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HIV-positive patients have an estimated twofold increased risk of acute myocardial infarction and coronary heart disease (CHD). While traditional cardiovascular risk factors and the effects of HIV and chronic inflammation all play a role, the contribution of long-term exposure to antiretroviral (ARV) agents is becoming clear. Methods: We performed a retrospective case\u2013control study of HIV-positive patients seen from January 1996 to December 2009 to evaluate the impact of HIV suppression and exposure to specific ARVs on the incidence of CHD. Results: Cases (n = 68) were HIV-positive with evidence of CHD. Two age- and sex-matched HIV-positive controls (n = 136) without a diagnosis of CHD were assigned for each case. The cumulative incidence of CHD in the period covered by the study was 3.8%, with an incidence of 8.5 cases per 1000 patient-years of follow up. Cases had an increased likelihood of having hypertension (odds ratio (OR): 6.62, P &amp;lt; 0.001), a family history of CHD (OR: 5.82, P &amp;lt; 0.001), lower high-density lipoprotein levels (OR: 0.28, P = 0.025) and higher Framingham risk scores compared with controls. Following adjustment for traditional cardiovascular risk factors, the presence of CHD was significantly associated with the current use of abacavir (OR: 2.10, P = 0.03). Protease inhibitor therapy, HIV viral load and duration of known HIV infection were not predictive of CHD in our patient population. Conclusions: Our data add to the evidence that abacavir use is associated with CHD in HIV-positive patients in Australia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1071\/sh12081","type":"journal-article","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T23:31:49Z","timestamp":1356046309000},"page":"97-101","source":"Crossref","is-referenced-by-count":9,"title":["Abacavir exposure and cardiovascular risk factors in HIV-positive patients with coronary heart disease: a retrospective case\u2013control study"],"prefix":"10.1071","volume":"10","author":[{"given":"Janine M.","family":"Trevillyan","sequence":"first","affiliation":[{"name":"AInfectious Diseases Unit, The Alfred Hospital, 55 Commercial Road, Melbourne, Vic. 3004, Australia."},{"name":"CCorresponding author. Email: j.trevillyan@alfred.org.au"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen C.","family":"Cheng","sequence":"additional","affiliation":[{"name":"AInfectious Diseases Unit, The Alfred Hospital, 55 Commercial Road, Melbourne, Vic. 3004, Australia."},{"name":"BDepartment of Infectious Diseases, Faculty of Medicine, Nursing and Health Science, Monash University, Vic. 3145, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Hoy","sequence":"additional","affiliation":[{"name":"AInfectious Diseases Unit, The Alfred Hospital, 55 Commercial Road, Melbourne, Vic. 3004, Australia."},{"name":"BDepartment of Infectious Diseases, Faculty of Medicine, Nursing and Health Science, Monash University, Vic. 3145, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"67","published-online":{"date-parts":[[2012,12,21]]},"reference":[{"issue":"5","key":"2025102617051631600_R1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/00126334-200208150-00002","article-title":"Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?","volume":"30","author":"Klein","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"2025102617051631600_R2","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1210\/jc.2006-2190","article-title":"Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease.","volume":"92","author":"Triant","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025102617051631600_R3","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s10461-008-9449-2","article-title":"Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation.","volume":"14","author":"Tesoriero","year":"2010","journal-title":"AIDS Behav"},{"issue":"5","key":"2025102617051631600_R4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/QAD.0b013e328325a87c","article-title":"HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction.","volume":"23","author":"Francisci","year":"2009","journal-title":"AIDS"},{"issue":"21","key":"2025102617051631600_R5","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction.","volume":"349","author":"Friis-Moller","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"2025102617051631600_R6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/0003-4819-145-6-200609190-00003","article-title":"Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City.","volume":"145","author":"Sackoff","year":"2006","journal-title":"Ann Intern Med"},{"issue":"1","key":"2025102617051631600_R7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/QAI.0b013e31819ff0e6","article-title":"Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.","volume":"51","author":"Brothers","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"17","key":"2025102617051631600_R8","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction.","volume":"356","author":"Friis-Moller","year":"2007","journal-title":"N Engl J Med"},{"issue":"22","key":"2025102617051631600_R9","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1136\/hrt.2009.177774","article-title":"HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies.","volume":"95","author":"Hulten","year":"2009","journal-title":"Heart"},{"issue":"10","key":"2025102617051631600_R10","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1086\/644769","article-title":"Simplification of antiretroviral therapy with tenofovir\u2013emtricitabine or abacavir\u2013lLamivudine: a randomized, 96-week trial.","volume":"49","author":"Martin","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2025102617051631600_R11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine.","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"18","key":"2025102617051631600_R12","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories.","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"issue":"9622","key":"2025102617051631600_R13","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D : A : D study: a multi-cohort collaboration.","volume":"371","author":"Sabin","year":"2008","journal-title":"Lancet"},{"issue":"10","key":"2025102617051631600_R14","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/QAD.0b013e328347fa16","article-title":"Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.","volume":"25","author":"Choi","year":"2011","journal-title":"AIDS"},{"issue":"2","key":"2025102617051631600_R15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1468-1293.2009.00751.x","article-title":"Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.","volume":"11","author":"Obel","year":"2010","journal-title":"HIV Med"},{"issue":"1","key":"2025102617051631600_R16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/cid\/cir269","article-title":"Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.","volume":"53","author":"Bedimo","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"14","key":"2025102617051631600_R17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/archinternmed.2010.197","article-title":"Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case\u2013control study nested within the French Hospital Database on HIV ANRS cohort CO4.","volume":"170","author":"Lang","year":"2010","journal-title":"Arch Intern Med"},{"issue":"16","key":"2025102617051631600_R18","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1097\/QAD.0b013e328349c6ee","article-title":"Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.","volume":"25","author":"Cruciani","year":"2011","journal-title":"AIDS."},{"issue":"8","key":"2025102617051631600_R19","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1093\/infdis\/jir509","article-title":"Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy.","volume":"204","author":"Satchell","year":"2011","journal-title":"J Infect Dis"},{"issue":"10","key":"2025102617051631600_R20","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/j.1468-1293.2009.00733.x","article-title":"Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy.","volume":"10","author":"Kristoffersen","year":"2009","journal-title":"HIV Med"},{"issue":"14","key":"2025102617051631600_R21","doi-asserted-by":"publisher","first-page":"F17","DOI":"10.1097\/QAD.0b013e32830fe35e","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.","volume":"22","author":"The SMART\/INSIGHT and the D : A : D Study Groups","year":"2008","journal-title":"AIDS"},{"issue":"3","key":"2025102617051631600_R22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1136\/tc.2009.032839","article-title":"Burden of smoking on cause-specific mortality: application to the Nurses\u2019 Health Study.","volume":"19","author":"Kenfield","year":"2010","journal-title":"Tob Control"}],"container-title":["Sexual Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/10\/2\/97\/1254336\/sh12081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/10\/2\/97\/1254336\/sh12081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:05:21Z","timestamp":1761512721000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/sh\/article\/10\/2\/97\/184818\/Abacavir-exposure-and-cardiovascular-risk-factors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,21]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4,12]]}},"URL":"https:\/\/doi.org\/10.1071\/sh12081","relation":{},"ISSN":["1448-5028","1449-8987"],"issn-type":[{"type":"print","value":"1448-5028"},{"type":"electronic","value":"1449-8987"}],"subject":[],"published":{"date-parts":[[2012,12,21]]}}}